Craif raises 5.3 billion yen in Series D to expand Bio-AI cancer detection

Bio-AI startup Craif has announced a Series D funding round totaling approximately 5.3 billion yen, bringing its total funding since inception to roughly 14.2 billion yen. The global round was co-led by Granite Integral Capital and Towns Co., Ltd., with participation from investors in Singapore, the United States, and Japan.

The capital is intended to accelerate R&D for its urine analysis platform, expand domestic operations in Japan, and support the product launch in the United States. To strengthen its US presence, Craif has established a bio-AI lab in San Diego and appointed key leadership, including CFO Takeo Mukai and Chief Medical Officer (CMO) Nicholas “Nick” Bevins, MD, PhD.

Dr. Bevins, an expert in clinical pathology and laboratory medicine, will lead clinical development strategies and oversee CLIA-certified laboratory operations in the US. This move supports Craif’s mission to enable early cancer detection, specifically focusing on pancreatic cancer through the analysis of urinary microRNA.